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monthly (p = 0.001). In contrast, AVJ ablations increased. During the same time periods,
an average of 6 AVJ ablations were performed each month prior versus a average of 10
after the trial data were presented (p = 0.001).
We conclude that AFFIRM and RACE trial data resulted in an early change in the man-
agement of patients with AF at these 2 institutions with a shift in practice towards a rate
control strategy.
9:00 a.m.
875-3 Suppression of Paroxysmal Atrial Tachyarrhythmias: 
Results of the SOPAT Trial
Monica Patten, Renke Maas, Bernd Lüderitz, Frank Sonntag, R. Hatala, M. Dluzniewski, 
G. Opolski, Thomas Meinertz, University Hospital Hamburg, Eppendorf, Hamburg, 
Germany
SOPAT is a prospective, double-blind, randomized trial to answer the following questions:
1. What is the average rate of spontaneous events of symptomatic atrial fibrillation
(sAF)? 2. Does treatment with sotalol or quinidine + verapamil significantly reduce the
recurrence rate of sAF? 3. How safe are these drugs?
Over 60 months 1033 pts. (mean age 60 yrs, 63% male, 12% heart failure) presenting at
least one episode of sAF one month prior to enrolement were recruted in 171 centres in
Germany, Poland and the Slovak Republic. Pts. were randomized to either 160 mg
sotalol bid (262 pts.), 160 mg quinidine + 80 mg verapamil (Q+V) bid (263 pts.), Q+V tid
(256 pts.) or placebo (252 pts.). Pts. received an ECG recorder (RhythmCard®, Instro-
medix) to record one 1-min ECG daily and in case of symptoms. ECGs were transmitted
by telephone to a central analysis unit together with pts. symptoms. The primary endpoint
was defined as the time to first recurrence of sAF or study discontinuation. Secondary
endpoint was the number of days with AF. During the one year follow-up 296260 Tele-
ECGs were transmitted and analysed.
The mean follow-up period was 233 ± 152 d. Premature study termination was highest in
the placebo group with 59% vs. 41% under Q+V tid, and 42% under Q+V bid and sotalol.
Regarding the primary endpoint all active treatments were superior to placebo and equiv-
alent to each other. A total of 756 pts. reached the primary endpoint within 106 ± 9 d
(mean ± SEM) under placebo, vs. Q+V tid: 150 ± 10 d (p= 0.0061), vs. Q+V bid: 149 ± 11
d (p= 0.0006), vs. Sotalol: 146 ± 9 d (p= 0.0007). Burden of sAF, determined as the rela-
tive number of days with sAF, was significantly reduced in all treatment groups compared
to placebo (mean ± SD: 6.1 ± 13.5)vs. Q+V tid (3.4 ± 12, p=0.0001), Q+V bid (4.5 ± 12.3,
p=0.008), and Sotalol (2.9 ± 6.5, p=0.026). A total of 6 deaths, 18 syncopes, and 1 ven-
tricular tachycardia occurred with a comparable risk profile for all treatment groups.
In conclusion, treatment with Q+V is equivalent to sotalol in reducing the recurrence rate
of symptomatic AF with a low risk of life-threatening events in pts. with lone AF or minimal
structural heart disease.
9:15 a.m.
875-4 The Incidence of Cerebral Embolism After 
Percutaneous Occlusion of the Left Atrial Appendage: A 
Serial and Prospective Study Using Cerebral Magnetic 
Resonance Imaging Scanning
Heyder Omran, Harald Schmidt, Peter Bernhardt, Christoph Hammerstingl, Stephanie 
Kuntz-Hehner, Thorsten Sommer, Berndt Lüderitz, David Hardung, University of Bonn, 
Bonn, Germany
Background: Percutaneous left atrial appendage (LAA) occlusion has been introduced as
an alternative treatment in patients with atrial fibrillation and increased thromboembolic
risk. However, the long term risk of cerebral embolism under this new treatment is
unknown. The aim of the study was to evaluate the long-term risk of cerebral embolism
by serial cerebral MRI scanning.
Methods: 20 Patients with contraindications to warfarin or bleeding complications under
oral anticoagulation were enrolled in the study. Serial neurological and echocardio-
graphic examinations were undertaken prior to and during the procedure and in addition
at 1 month, 2 months, 6 and 12 months. Cerebral MRI including diffusion weighted
sequences was performed prior to the procedure, 48 hours after and 6 and 12 months
after the procedure to assess for cerebral microembolism.
Results: Cerebral MRI performed prior to the occlusion procedure detected the presence
of former cerebral embolism in 8 out of the 20 patients. Follow-up MRI studies excluded
the presence of new cerebral microembolism in all patients. TTE and TEE examinations
did not reveal de novo thrombus formation in the LA or thrombotic appositions on the sur-
face of the occlusion device.
Conclusions: Long term follow-up of patients with occlusion of the left atrial appendage
did not reveal cerebral thromboembolism on serial cerebral MRI. Percutaneous left atrial
appendage occlusion is an alternative treatment in patients at high risk of thromboembo-
lism and contraindications to oral anticoagulation therapy.
9:30 a.m.
875-5 Randomized Trial of Two Antiarrhythmic Agents 
(Amiodarone and Sotalol) in Patients With Atrial 
Fibrillation for Whom Direct Current Cardioversion Is 
Planned
Kunadian Vijayalakshmi, Michael J. Stewart, James A. Hall, Adrian Davies, Mark A. de 
Belder, The James Cook University Hospital, Middlesbrough, United Kingdom
Anti-arrhythmic agents enhance maintenance of sinus rhythm (SR) following direct cur-
rent cardioversion (DCC) for atrial fibrillation (AF) but there are few comparative trials.
Aims: (1)To establish whether taking amiodarone or sotalol (at standard clinical doses) is
better at achieving chemical cardioversion within the 6 weeks prior to planned DCC. (2)To
establish whether DCC is more likely to be successful on an anti-arrhythmic agent and
(3) to establish whether patients successfully cardioverted to SR are more likely to stay in
SR over 6 months if taking a drug and if so to establish whether one agent is better than
the other.
Methods: Randomised, prospective, non-blinded, controlled study of treatment with
either amiodarone, sotalol or no anti-arrhythmic agent to start 6 weeks prior to DCC, and
treatment to continue for a further 6 months. Patients with time of onset of AF within the
last 1 year were included. 94 patients were enrolled in the study (nil group n=31, sotalol
n=36 and amiodarone n=27). Follow up visits were at 6 weeks and 6 months post DCC.
Results: A total of 7 (25%) patients in the amiodarone group (A), 7 (19%) patients in the
sotalol group (S) were chemically cardioverted to SR, compared to none (0%) in the no
anti-arrhythmic group (N) [p=0.002 (AvN), 0.01 (SvN), 0.5 (AvS) respectively]. A total of
26/29 (90%) patients in the sotalol group were successfully cardioverted to SR compared
to 15/20 (75%) patients in the amiodarone group and 23/31 (74%) patients in the no anti-
arrhythmic group [p=0.03 (SvA), 0.05 (SvN), 0.9 (AvN) respectively]. At 6 month review
17 (62%) patients in the amiodarone group were in SR compared to 14 (38%) patients in
sotalol group and only 5 (16%) patients in the no anti-arrhythmic group [p=0.05 (AvS),
<0.05 (AvN) respectively]. Intention to treat and actually treated analysis gave similar
results.
Conclusion: Treatment with either amiodarone or sotalol for 6 weeks had equal efficacy
in achieving chemical cardioversion before planned DCC. Sotalol significantly increased
the chance of DCC producing SR. After successful cardioversion, amiodarone signifi-
cantly reduced the rate of reversion to AF and increased the chance of being in SR at 6
months
9:45 a.m.
875-6 Early Recurrence of Arrhythmia Is Common in Patients 
Taking Amiodarone or Type IC Agents for Treatment of 
Atrial Fibrillation or Atrial Flutter
Thomas H. Hauser, Duane S. Pinto, Mark E. Josephson, Peter Zimetbaum, Beth Israel 
Deaconess Medical Center, Boston, MA, Harvard Medical School, Boston, MA
Background: Amiodarone use for the prevention of recurrent atrial fibrillation or flutter
requires drug loading over several weeks. The rate of recurrent arrhythmia during amio-
darone loading has not been investigated. We compared the rates of recurrent arrhyth-
mia in patients treated with amiodarone and type IC agents, which do not require drug
loading.
Methods: We prospectively monitored a cohort of patients with ambulatory loop record-
ers during outpatient drug loading after spontaneous or electrical cardioversion to sinus
rhythm.
Results: The study cohort comprised 339 patients who were treated with amiodarone
(212), propafenone (64) or flecainide (63). Patients taking amiodarone were older (74 ±
11 vs. 59 ± 12, p <0.001) and more likely to have left ventricular dysfunction (80 [39%] vs.
8 [7%], p <0.001). Arrhythmia recurred in 106 (31.3%) and was persistent in 44 (13.0%).
The incidence of recurrent arrhythmia at 15 days was much less in patients treated with
amiodarone compared to those treated with a type IC agent (25.4% vs. 42.5%, p <
0.001) (Figure). Persistent arrhythmia was also much less in patients treated with amio-
darone (9.9% vs. 19.2% at 15 days, p = 0.011). Of those with recurrent arrhythmia, 58
(55%) were asymptomatic.
Conclusion: Recurrent arrhythmia is common and frequently asymptomatic during drug
loading with both amiodarone and type IC agents but is usually not persistent. The inci-
dence of recurrent arrhythmia during drug loading is much less with amiodarone com-
pared to type IC agents. 
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New Insights Into Resynchronization 
Therapy
Wednesday, March 10, 2004, 10:30 a.m.-Noon
Morial Convention Center, La Louisiane C
10:30 a.m.
879-1 Acute Changes in Aortic Time-Velocity-Integral With 
Cardiac Resynchronization Therapy Predict Clinical 
Outcome
Sanjeev Garhwal, Alan Waggoner, Navinder Sawhney, Mohit Chawla, Mitchell Faddis, 
Washington University, St. Louis, MO
Background: Cardiac resynchronization therapy (CRT) can improve symptoms in patients
(pts) with end-stage heart failure and ventricular conduction delay. However, up to one-
third of pts who undergo CRT fail to have clinical improvement. We hypothesized that pts
who have an acute improvement in Doppler-determined aortic time-velocity-integral
(AoTVI) with CRT are more likely to have an improvement in NYHA class at follow up.
Methods: AoTVI was measured at baseline (without pacing) and with biventricular pacing
(VDD mode) by continuous-wave Doppler echocardiography in 30 consecutive pts who
received CRT. AV delay was 125+25ms for the group. All measurements were performed
within 24 hours after CRT. Left ventricular lead position was mid-lateral in 18/30 pts. Pts
were classified as responders (n=22) or non-responders (n=8) based on improvement in
NYHA class at a 3-month follow-up. Results: There were no significant differences
between responders and non-responders in baseline NYHA class (3.1+0.4 vs 2.8+0.4;
p=0.09), ejection fraction (25%+6% vs 26+7; p=0.58), age (57+11 yrs vs 63+14 yrs;
p=0.38) and AoTVI (16.9+3.2cm vs 19.8+5.6cm; p=0.13), respectively. The mean
decrease in NYHA class at follow up was 0.9 among responders. Responders had a sig-
nificantly higher percent improvement in AoTVI with CRT compared to baseline than non-
responders (22%+13% vs 5%+6%, respectively, p=0.003). A >10% improvement in
AoTVI with CRT accurately identified pts with improved NYHA class at 3-month follow-up
(sensitivity 86%, specificity 88%, positive predictive value 95% and negative predictive
value 70%). Conclusion: A 10% improvement in AoTVI with CRT is a sensitive and spe-
cific criterion for predicting pts who will benefit from CRT. Measurement of AoTVI during
placement of the left ventricular lead could provide a simple method to assess efficacy of
CRT.
10:45 a.m.
879-2 Does Heart Rate Regularization With Biventricular 
Pacing Itself Enhance Net Cardiac Function in Heart 
Failure Patients With Chronic Atrial Fibrillation?
Ilan Hay, Vojta Melenovsky, Barry J. Fetics, Joshua Hare, Daniel Judge, Andrew Kramer, 
Craig Reister, Joe Pastore, Rick Conville, David A. Kass, Ronald Berger, Johns Hopkins 
Medical Institution, Baltimore, MD, Guidant Co., St. Paul, MN
Ventricular pacing in patients with atrial fibrillation (AF) reduces RR interval variability
(rate regularization) but can adversely influence contractile function.The latter may be
ameliorated by bi-ventricular pacing, but the added impact of rate regularization has
remained unclear. To test this, we studied nine patients with chronic AF (s/p AV-node
ablation, or with bradycardia) and cardiac failure (EF<30%). Bi-ventricular pacing was
instituted using an RV-apical and LV-postero-lateral lead. AF (using Bi-V pacing) was
simulated by a Poisson distribution of RR intervals with a mean of 80 bpm (RR: 400-
1500ms). LV and aortic micro-manometer pressures were assessed during two-minutes
recordings of simulated AF and compared to fixed rate biventricular pacing and RV pac-
ing at the same mean rate (Table).
Mean systolic function during simulated-AF was not statistically different (p>0.4 for all
comparisons, paired t-test) from that with constant rate Bi-V pacing. Diastolic function
(mean LV dp/dt min) differed between Bi-V fixed rate and Pseudo AF pacing. Bi-V pacing
improved LV performance compared to RV pacing. Thus, while rate regularization alone
narrows temporal hemodynamic variance, averaged cardiac performance is minimally
altered compared to constant rate pacing. This suggests that hemodynamic benefits of
AF pacing in heart failure patients are from BiV versus RV pacing, whereas rate regular-
ization has little effect on mean function.
11:00 a.m.
879-3 Utility of Atrioventricular Delay Optimization in Patients 
Undergoing Cardiac Resynchronization Therapy
Navin Kedia, Deborah Agler, Zoran B. Popovic, Betty Ching, Bruce Wilkoff, Richard A. 
Grimm, Cleveland Clinic Foundation, Cleveland, OH
Background: Optimization of the atrio-ventricular delay (AV delay) using Doppler
echocardiography in patients undergoing Cardiac Resynchronization Therapy (CRT) is
currently being performed inconsistently and with little data to either support or refute its
utility. We reviewed our experience with AV optimization at the Cleveland Clinic in an
attempt to provide insights into the potential utility of performing this procedure.
Methods: Data was collected from 116 patients who underwent an AV optimization
within 3 months of implant at the Cleveland Clinic between 1999 and 2002. All patients
arrived to the echocardiography laboratory with an AV delay empirically programmed by
the operator at the time of the biventricular pacemaker procedure. The AV delay was then
optimized using the method described by Ritter and colleagues and modified so as to tar-
get stage I diastolic filling as determined by Doppler echocardiography in those cases in
which the Ritter derived “optimal AV delay” was unable to be calculated due to technical
reasons. Baseline clinical characteristics, AV delay at baseline as well as the final setting
were recorded along with the stage of diastolic filling.
Results: Between 1999 and 2002 276 patients underwent a biventricular pacing implant
at the Cleveland Clinic, 116 of which also underwent an AV optimization procedure within
90 days of their implant. The average, median and range of AV delays were 129, 130, 50-
180 msec respectively at baseline while the average, median and range of final AV delay
settings were 133, 130, 50-250 msec respectively. In 78% of cases the final AV delay set-
ting was within 50 msec of the baseline setting, whereas in 22% of the cases the final
setting was between 50-250 msec.
Conclusion: AV delay optimization using Doppler echocardiography and the Ritter
method in patients undergoing CRT results in a significant change in the final AV delay
setting in only 22% of the cases. These data would suggest that AV delay optimization is
not necessary in most patients undergoing CRT. Further investigation attempting to tar-
get patients likely to benefit from an AV optimization procedure is needed.
11:15 a.m.
879-4 Cardiac Resynchronization Therapy Improves Sleep 
Related Breathing Disorders in Patients With Chronic 
Heart Failure
Karlheinz Seidl, Monika Rameken, Thorsten Becker, Margit Vater, Jochen Senges, Heart 
Center, Ludwigshafen, Germany
Background: About 40 - 50% of patients (pts) with advanced heart failure (CHF) present
with sleep related breathing disorders (SRBD) primarily they present with central sleep
apnea syndrome.
Aim of the study was 1) to assess, how many pts with CHF have additionally a SRBD. 2)
to evaluate the effect of cardiac resynchronisation therapy (CRT) on SRBD in these pts.
Methods: Overnight polysomnography was performed in 55 pts with CHF and left bundle
branch block (41 male; 65 ± 11 years, reduced ejection fraction (26 ± 6%) and NYHA III).
If the apnea/hypopnea index (AHI) was > 10 during baseline polysomnography "with CRT
off", a second overnight polysomnography was performed "with CRT on".
Results: 21 pts (38%) had a AHI >10, in 15 pts (71%) a central and in 6 pts (29%) a
obstructive form of SRBD was present at baseline. Compared to baseline values AHI
was significantly improved from 49 ± 35 to 14 ± 10 (p=0.01), whereas the noctural mini-
mal oxygen saturation significantly increased from 85 ± 6% to 91 ± 5% (p=0.02) with
"CRT on". No improvement was seen in pts with an obstructive form of SRBD.
RV  Bi-V
Mean ± S.D Fixed Rate Fixed Rate Pseudo AF
LV dp/dt max (mmHg/sec)  809 ± 110  978 ± 126.5* 975.8 ± 89.5
Arterial Pulse Pressure (mmHg)  33.6 ± 6.6  37.5 ± 9.8  37.5 ± 7.6
Arterial Mean Pressure (mmHg)  79.5 ± 14.7  83.3 ± 11.4  82.2 ± 11.6
Arterial Systolic Pressure (mmHg)  99.3 ± 12.7 105.5 ± 10 104.2 ± 10.2
LV end diastolic pressure (mmHg)  21.8 ± 8.02  19.3 ± 7.06*  18.9 ± 6.6
LV dp/dt min (mmHg/sec) -785.1 ± 170.2 -965.6 ± 186* -912 ± 185¶
* p<0.05 ( compared to RV)
¶ p<0.05 ( Fixed rate compared to Pseudo AF)
